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 Abstract 
  Variant Creutzfeldt-Jakob disease (vCJD) was first reported in the UK in 1996. Here, we report 
the first Turkish case of vCJD. A 47-year-old man, who has never lived outside of Turkey and had 
had no transfusion, was admitted to the University Hospital with speech disorder, cognitive de-
cline and ataxia following depression, irritability, and personality change. The immunoassay of 
the 14-3-3 protein in the cerebrospinal fluid was negative. Brain magnetic resonance imaging 
revealed high-signal lesions involving the bilateral caudate and lentiform nucleus on T2- and 
diffusion-weighted imaging. The patient developed akinetic mutism 10 months after disease 
onset. The clinical presentation and neuroimaging findings were compatible with the vCJD 
cases reported since 1996 and met the World Health Organization’s case definition for probable 
vCJD.    Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  Creutzfeldt-Jakob disease (CJD), which is characterized by progressive dementia with 
a fatal and incurable course, is the most common human prion disease. There are 4 types 
of this disease: the sporadic (85%), familial (10–15%), iatrogenic (1%), and variant types  [1] . 
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Variant Creutzfeldt-Jakob disease (vCJD) was first reported in 1996 in the United King-
dom and has been causally linked to the consumption of cattle products contaminated 
with the bovine spongiform encephalopathy (BSE) agent   [2]  . To date, more than 215 cases 
of vCJD have been identified worldwide, including in the UK, France, Ireland, Italy, the 
USA, Canada, Saudi Arabia, Japan, The Netherlands, Portugal, Spain, and Taiwan. In the 
present paper, we report the clinical and radiological data of the first Turkish case of vCJD.
  C a s e   R e p o r t  
 A 47-year-old man, who was previously healthy and had no history of psychiatric or neu-
rological disorders before the onset of this disease, presented with a 6-month history of pro-
gressive behavioral and personality changes, depression, and cognitive decline. His relatives 
reported that personality changes were his first symptoms. He had been a rigorous, disci-
plined, and frugal person, who was dependable at work and a valued member of his family; 
however, he became aggressive, extravagant, foul-mouthed, sexually disinhibited, and angry. 
His wife reported that the patient would have sudden outbursts of agitation, and 2 months 
later, these outbursts were followed by paranoid behaviors and possessiveness. Due to the 
psychiatric nature of his complaints, he was admitted to a psychiatry clinic, where he was 
diagnosed as having a manic disorder and was given atypical antipsychotic drugs. Three 
months later, the patient exhibited gait changes, ataxia and dysarthria, severe forgetfulness, 
difficulties in swallowing and eating, and incontinence. The patient developed involuntary 
movements in both of his feet, with dystonic aversion-inversion posturing and occasional 
erratic movements. He became dependent and apathetic and exhibited regressive behaviors. 
The patient also exhibited visual hallucinations, during which he reported seeing animals. 
Some of these complaints may have been side effects from his medication and, consequently, 
several of the patient’s medications were stopped or changed.
As a result of the progressive deterioration of the patient’s general status, his relatives 
transferred him to the Psychiatry Department of our University Hospital. After the neuro-
logical examination conducted at the Psychiatry Clinic, he was diagnosed as having rapid 
progressive dementia with early onset and was hospitalized at the Neurology Clinic. As re-
ported in the patient’s medical history, he had never been exposed to cadaveric pituitary hor-
mones, had never undergone a neurosurgical procedure, organ or tissue grafts, or a blood 
transfusion, and had never travelled to the UK or to any country with reported incidences 
of BSE.
    The neurological examination revealed that the patient was disorientated in place and 
time. In addition, he was mute. Nystagmus and conjugate gaze dysfunction were present, as 
were cerebellar ataxia, dysmetria, and dysdiadochokinesia. The patient’s tone was slightly 
increased in his lower limbs, and his plantar responses were extensor.
  The level of protein in his cerebrospinal fluid was increased, and no 14-3-3 protein was 
detected. An electroencephalogram showed a generalized slowing of wave, which was 
more evident in the left hemisphere, but did not have any periodic complexes. He was re-
ferred to the Radiology Department for cerebral MRI. On T2-weighted images and fluid-
attenuated inversion recovery (FLAIR) images, hyperintense signal changes in the bilat-
eral caudate nuclei (white arrows) and the lentiform nucleus (black arrows) were seen. In 
addition, hyperintensity in the bilateral thalamic region was less prominent than in the 
previously described areas (  fig. 1  a–c). Cortical hyperintensity was noted on diffusion-
weighted imaging.
    Genotyping of the prion protein gene (PRNP) identified a P102L mutation and hetero-
zygosity for methionine at codon 129.431
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    The patient did not want to undergo a brain biopsy, and we continued to follow his
progress at his home. At the time this report was written, the patient was alive, mute, and
on bed rest.
  Discussion 
 The patient described in the present report was the first probable case of vCJD in Turkey. 
The clinical features of this patient are consistent with the vCJD cases that have been identi-
fied in the UK and France, including psychiatric manifestations at the disease onset, a de-
layed occurrence of neurological signs, ataxia, and dementia   [3]  . In addition to the pulvinar 
sign that was present on the MRI and EEG, the patient fulfilled the WHO case definition for 
probable vCJD, the specificity of which is 100%   [4]  . Of note, a tonsil biopsy is not necessary 
if the clinical features and the MRI findings are compatible with vCJD, as the pulvinar sign 
is highly characteristic   [5]  .
  Sequencing analysis revealed that the patient had two different nucleotide changes in the 
coding region of the PRNP gene. The first one is the M129V polymorphism, and our patient 
was heterozygous for this alteration. Interestingly, all the patients who have undergone ge-
notyping up to now have been homozygous for methionine at codon 129. This polymor-
phism is associated with susceptibility to prion diseases   [6]  . The second one is the P102L 
mutation, which was first identified in affected members of two unrelated families with 
Gerstmann-Sträussler disease. P102L is one of the most common PRNP mutations and also 
related to CJD.
  This case highlights the difficulties in achieving an early diagnosis of vCJD. At the initial 
presentation, a variety of diagnoses were proposed, but vCJD was not considered in this pa-
tient. Instead, he was diagnosed as having an affective disorder at the psychiatry clinic. The 
delayed neurological signs in this patient pointed to the possibility of progressive dementia, 
which is not surprising given the frequency of psychiatric features that are observed by pri-
mary care physicians. These clinical features are often misleading. Almost half of the cases 
of vCJD were reviewed by a psychiatrist prior to the patients’ neurological referral  [7] . A neu-
  Fig. 1.   MRI shows hyperintensity in the bilateral caudate (white arrows) and bilateral lentiform nucleus 
(black arrows) as well as in the bilateral thalamus (curved arrow) on axial T2-weighted image (  a )  and 
coronal FLAIR image (  b  ). Ribbon-shaped hyperintense signals in the right central sulcus and bilateral 
parietal cortex at the convexity is seen on diffusion-weighted imaging (arrows) (b = 1,000 s/mm  2 )  ( c ). 432
Dement Geriatr Cogn Disord Extra 2011;1:429–432
 DOI:  10.1159/000332024 
EXTRA
  Adapınar et al.: First Case of vCJD in Turkey 
www.karger.com/dee
    © 2011 S. Karger AG, Basel
  Published online: December 24, 2011 
rological etiology was usually suspected promptly after the patients developed objective neu-
rological features, which resulted in a neurological referral in all of the cases. The single most 
important determinant of early diagnosis was the presence of objective neurological features. 
For this reason, all physicians must be careful when diagnosing rapidly progressing demen-
tia that begins at a young age.
    The results presented in this report indicate that patients with vCJD are still seen in the 
medical community. In the present study, we have reported the first Turkish vCJD case, 
which appeared 15 years after the first case in the UK.
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